On the day before the symposium (Thursday, July 30, 2026), an affiliated workshop organized by IQ Japan Subteam will be held in meeting rooms at Pfizer Japan Inc. (Shinjuku, Tokyo), with planning support from PMDA and the Japan Pharmaceutical Manufacturers Association. Participation is free of charge. Titled “A New Era for MIDD Opened by the ICH M15 Guideline,” the workshop combines lectures on implementing the ICH M15 Guideline (currently at Step 4) with in-person group work on Model Credibility assessment, aiming to help participants experience practical responses for smooth implementation. · Registration period: Thursday, June 4 – Tuesday, June 30, 2026 · Registration URL: https://forms.gle/NPPugiijhuGZG4CU6 · Session information: Download (English PDF) Details and pre-assignments for the Expert Session group work will be sent to registrants after the registration period closes. Capacity is approximately 60 participants; excluding PMDA attendees, we ask that each organization limit participation to about two people.
The poster presentation schedule has been released. Please see the details below. Please note that advance registration is required to present a poster. ■ Poster Presentation Schedule (Tentative) Submission opens: May 14, 2026 Submission deadline: June 30, 2026 Notification of acceptance: July 10, 2026
Advance registration is now open. If you wish to participate, please complete your registration by 23:59 on July 30, 2026. Registration Fee (Advance): General JPY 9,000 / Student JPY 5,000 Banquet Fee: General JPY 8,000 / Student JPY 3,000 After this deadline, an on-site fee (flat rate of JPY 12,000) must be paid in cash at the venue. Advance registration is recommended to take advantage of the discounted rates.
スピーカー・プログラム情報
Speaker and Program Information
スピーカー情報、プログラムは現在編集中です。公開次第こちらでご案内します。
Speaker information and the scientific program are currently in preparation. Updates will be posted on this website as soon as they become available.
Pharmacometrics plays a pivotal role in drug development and clinical decision-making by quantifying the relationships among dosing, efficacy, and safety. This symposium brings together experts in pharmacokinetics, pharmacodynamics, systems biology, statistics, and medicine to explore how mathematical modeling and data science are shaping next-generation therapeutics.
We will highlight breakthroughs such as virtual patients and populations, in silico clinical trials, biomarker discovery, and AI-enabled modeling that shorten development timelines. The program fosters dialogue between academia and industry to tackle shared challenges and ignite collaborative innovation.
組織・委員 / Organizing Team
大会長 / Chairs
岩見 真吾(名古屋大学) / Shingo Iwami (Nagoya University)
三好 聡(ファイザー R&D 合同会社) / So Miyoshi (Pfizer R&D Japan G.K)
前田 和哉(北里大学) / Kazuya Maeda (Kitasato University)
運営委員会 / Executive Committee
三好 聡(ファイザー R&D 合同会社) / So Miyoshi (Pfizer R&D Japan G.K)